Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
8.35
+0.14 (1.71%)
At close: Sep 16, 2025, 4:00 PM EDT
8.51
+0.16 (1.92%)
Pre-market: Sep 17, 2025, 4:54 AM EDT
Kura Oncology Stock Forecast
Stock Price Forecast
The 11 analysts that cover Kura Oncology stock have a consensus rating of "Buy" and an average price target of $24.45, which forecasts a 192.81% increase in the stock price over the next year. The lowest target is $10 and the highest is $40.
Price Target: $24.45 (+192.81%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 11, 2025.
Analyst Ratings
The average analyst rating for Kura Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 3 | 5 | 5 | 5 | 6 | 6 |
| Hold | 2 | 2 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 12 | 12 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Sep 4, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $28 → $24 | Buy | Maintains | $28 → $24 | +187.43% | Aug 11, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 26, 2025 |
| Wedbush | Wedbush | Buy Reiterates $36 | Buy | Reiterates | $36 | +331.14% | Jun 20, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $28 | Buy | Reiterates | $28 | +235.33% | Jun 4, 2025 |
Financial Forecast
Revenue This Year
86.35M
from 53.88M
Increased by 60.25%
Revenue Next Year
220.27M
from 86.35M
Increased by 155.10%
EPS This Year
-2.58
from -2.02
EPS Next Year
-2.63
from -2.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 171.2M | 473.8M | |||
| Avg | 86.3M | 220.3M | |||
| Low | 29.1M | 31.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 217.6% | 448.7% | |||
| Avg | 60.3% | 155.1% | |||
| Low | -45.9% | -64.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.65 | -1.03 | |||
| Avg | -2.58 | -2.63 | |||
| Low | -3.32 | -4.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.